Mark Anthony McCamish - Aug 11, 2023 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Director
Signature
/s/ Jerad G. Seurer, Attorney-in-Fact
Stock symbol
AVDL
Transactions as of
Aug 11, 2023
Transactions value $
-$432,614
Form type
4
Date filed
8/15/2023, 04:13 PM
Previous filing
Aug 3, 2023
Next filing
Dec 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVDL ADSs Sale -$433K -29K -16.94% $14.93 142K Aug 11, 2023 By Matthew 5 LLC F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the Issuer; ADSs may be represented by American Depositary Receipts.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.75 to $15.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F3 Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.